CA2910652C - Tafa4 compounds and uses thereof for treating pain - Google Patents

Tafa4 compounds and uses thereof for treating pain Download PDF

Info

Publication number
CA2910652C
CA2910652C CA2910652A CA2910652A CA2910652C CA 2910652 C CA2910652 C CA 2910652C CA 2910652 A CA2910652 A CA 2910652A CA 2910652 A CA2910652 A CA 2910652A CA 2910652 C CA2910652 C CA 2910652C
Authority
CA
Canada
Prior art keywords
pain
tafa4
protein
use according
neurons
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2910652A
Other languages
English (en)
French (fr)
Other versions
CA2910652A1 (en
Inventor
Aziz Moqrich
Marie-Claire Delfini
Annabelle Mantilleri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aix Marseille Universite
Centre National de la Recherche Scientifique CNRS
Original Assignee
Aix Marseille Universite
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aix Marseille Universite, Centre National de la Recherche Scientifique CNRS filed Critical Aix Marseille Universite
Priority to CA3235916A priority Critical patent/CA3235916A1/en
Publication of CA2910652A1 publication Critical patent/CA2910652A1/en
Application granted granted Critical
Publication of CA2910652C publication Critical patent/CA2910652C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A01K2217/077—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out heterozygous knock out animals displaying phenotype
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Environmental Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Molecular Biology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Biotechnology (AREA)
  • Anesthesiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CA2910652A 2013-05-06 2014-05-06 Tafa4 compounds and uses thereof for treating pain Active CA2910652C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3235916A CA3235916A1 (en) 2013-05-06 2014-05-06 Tafa4 compounds and uses thereof for treating pain

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13305592.1 2013-05-06
EP13305592.1A EP2801369A1 (en) 2013-05-06 2013-05-06 TAFA4 compounds and uses thereof for treating pain
PCT/EP2014/059247 WO2014180853A1 (en) 2013-05-06 2014-05-06 Tafa4 compounds and uses thereof for treating pain

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3235916A Division CA3235916A1 (en) 2013-05-06 2014-05-06 Tafa4 compounds and uses thereof for treating pain

Publications (2)

Publication Number Publication Date
CA2910652A1 CA2910652A1 (en) 2014-11-13
CA2910652C true CA2910652C (en) 2024-05-28

Family

ID=48428409

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2910652A Active CA2910652C (en) 2013-05-06 2014-05-06 Tafa4 compounds and uses thereof for treating pain
CA3235916A Pending CA3235916A1 (en) 2013-05-06 2014-05-06 Tafa4 compounds and uses thereof for treating pain

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3235916A Pending CA3235916A1 (en) 2013-05-06 2014-05-06 Tafa4 compounds and uses thereof for treating pain

Country Status (8)

Country Link
US (2) US9884088B2 (enExample)
EP (2) EP2801369A1 (enExample)
JP (1) JP6487419B2 (enExample)
CN (1) CN105209056B (enExample)
CA (2) CA2910652C (enExample)
DK (1) DK2994157T3 (enExample)
ES (1) ES2813629T3 (enExample)
WO (1) WO2014180853A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3270160B1 (en) * 2015-03-13 2020-03-18 Sysmex Corporation Method for detecting test substance and reagent kit used in said method
JP2021501334A (ja) * 2017-10-30 2021-01-14 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 電気化学的センサーを用いた、分析物の較正不要なインビボ測定
AU2019259798A1 (en) * 2018-04-24 2020-11-12 Neuracle Science Co., Ltd. Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment of neuropathic pain
WO2020064907A1 (en) * 2018-09-27 2020-04-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition reducing skin inflammation
CN109596818B (zh) * 2018-12-13 2024-03-19 丁蓉 一种基于电生理学分析当归四逆汤预防奥沙利铂神经毒性机制的研究方法
KR20220137009A (ko) * 2020-02-04 2022-10-11 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 염증 질환을 치료하기 위한 방법 및 약제학적 조성물
KR20230010622A (ko) * 2020-02-13 2023-01-19 더 유나이티드 스테이츠 오브 아메리카, 애즈 레프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 Piez02-매개 통증을 감소시키는 마가르산
TWI759788B (zh) * 2020-07-08 2022-04-01 台灣粒線體應用技術股份有限公司 萃取保護液用於自細胞分離粒線體並維持粒線體活性的用途
JP2024547029A (ja) 2021-12-17 2024-12-26 タファルジー・セラピューティクス 疼痛の処置における使用のためのペプチド及び方法
CA3242979A1 (en) * 2021-12-20 2023-06-29 Amgen Inc. DLL3 LINKING PEPTIDES AND THEIR USES
US20230302207A1 (en) * 2022-03-24 2023-09-28 Baxter International Inc. Dialysis system having thermoelectric heating
AR129441A1 (es) 2022-05-25 2024-08-28 Tafalgie Therapeutics Péptidos y métodos para el tratamiento del dolor
US20260041790A1 (en) * 2022-05-31 2026-02-12 Neuracle Genetics Inc. Composition for treating retinal or macular diseases
KR20250153765A (ko) 2023-02-17 2025-10-27 나오스 인스티튜트 오브 라이프 사이언스 피부 내성 역치를 증가시킬 수 있는 생태생물학적 화합물의 선택 방법
WO2025116606A1 (ko) * 2023-11-30 2025-06-05 주식회사 뉴라클제네틱스 신규한 케모카인-유사 단백질 단편
CN121249875B (zh) * 2025-10-13 2026-03-20 上海交通大学医学院附属仁济医院 外周神经系统中的Mas相关G蛋白耦联受体D在缓解阿片类药物耐受中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090077680A1 (en) * 2000-06-12 2009-03-19 Alejandro Abuin Genetically Engineered and Photyped Mice and Stem Cell Clones for Producing the Same
US20090136552A1 (en) * 2004-07-30 2009-05-28 Mette Gronborg Growth factors nsg28, nsg30, and nsg32

Also Published As

Publication number Publication date
JP2016519138A (ja) 2016-06-30
US20180110829A1 (en) 2018-04-26
EP2994157B1 (en) 2020-07-01
EP2801369A1 (en) 2014-11-12
WO2014180853A1 (en) 2014-11-13
CA2910652A1 (en) 2014-11-13
DK2994157T3 (da) 2020-08-24
ES2813629T3 (es) 2021-03-24
CN105209056A (zh) 2015-12-30
JP6487419B2 (ja) 2019-03-20
CA3235916A1 (en) 2014-11-13
EP2994157A1 (en) 2016-03-16
US9884088B2 (en) 2018-02-06
CN105209056B (zh) 2018-01-23
US20160113996A1 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
EP2994157B1 (en) Tafa4 compounds and uses thereof for treating pain
US9125862B2 (en) Methods for the treatment of Prader-Willi-like syndrome or non-organic failure to thrive (NOFITT) feeding disorder using an agonist of the oxytocin receptor
US8252748B2 (en) Peptide derived from neurotensin receptor 3 and use thereof in the treatment of psychiatric diseases
WO2018205927A1 (zh) 钾离子通道抑制剂治疗抑郁症的用途和药物组合物
ES2617309T3 (es) Métodos y ensayos de tratamiento de sujetos con eliminación, mutación o expresión reducida de SHANK3
Class et al. Patent application title: TAFA4 COMPOUNDS AND USES THEREOF FOR TREATING PAIN Inventors: Aziz Moqrich (Marseille, FR) Marie-Claire Delfini (Marseille, FR) Annabelle Mantilleri (Apt, FR)
CN102648977B (zh) 滤泡素抑制素样蛋白1在调节钠钾atp酶活性中的用途
JP2007530069A6 (ja) イオンチャネル
Kamalova Functional characterization of an AMPA receptor auxiliary subunit GSG1L in vivo
Rees Characterization of the 15q13. 3 Microdeletion and Its Effects on Neuronal Excitability, Astrocyte α7 Nicotinic Acetylcholine Receptor Dynamics, and Neuroinflammation
US20240209038A1 (en) Targeting piezo1 to treat inherited and age-related macular degenerations
Dong et al. Low-level expression of Cmyc in mature neurons: maintaining neuronal function and preventing neurodegeneration
US11878012B2 (en) Compositions and methods for treating traumatic brain injury
Lin Cell Type-Specific FGF13 Regulation of Neuronal Function
Serranilla Chloride Dysregulation and Impaired Gamma-Amino Butyric Acid Signaling in the Basal Ganglia in Huntington’s Disease
Ilaria et al. Voltage-independent GluN2A-type NMDA receptor Ca2+ signaling promotes audiogenic seizures, attentional and cognitive deficits in mice
Gandhi Organisation of Glutamatergic Inputs to Central Amygdala
De Rocco Pharmacological modulation of neuronal activity for the treatment of Rett syndrome
CN1937914A (zh) 离子通道
KR20220025810A (ko) 스미스-마제니스 증후군을 치료하기 위한 방법 및 조성물
Senese Role of Regulator of G-Protein Signaling Proteins in Serotonin and Opioid Mediated Behaviors
WO2015047512A1 (en) Inhibitors of cacna1a/alpha1a subunit internal ribosomal entry site (ires) and methods of treating spinocerebellar ataxia type 6
Heuermann The Role of HCN Channels and TRIP8b in Depression and Epilepsy
Lewis The role of TRIP8b in neuronal HCN channel trafficking and function
Al-Shammari Novel functions of schizophrenia-related dysbindin-1 in the subventricular zone

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190423

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250417

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250417

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260414

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260414